AMERICAN SHARED HOSPITAL SERVICES
| Revenue | $30.4M |
|---|---|
| Operating income | $-1.8M |
| Net income | $-1.1M |
| Free cash flow | $4.3M |
| Operating margin | -6.0% |
| Net margin | -3.7% |
| Return on equity | -4.9% |
| Period | TTM 2026-06-30 |
OpenFilings analyst
Our analyst
Agentic read of the latest earnings call — recommendation updates when we process a new transcript. Research synthesis, not investment advice.
Operational momentum is real—Q2 revenue rose 19.2% to $8.4 million, direct patient services grew 40% to $4.9 million, and first-half operating cash flow was $4.4 million—but profitability deteriorated, with adjusted EBITDA falling to $1.3 million and a $514,000 net loss. This is not yet a buy: the company remains dependent on a forbearance agreement, owes Fifth Third $15.5 million, and must refinance or potentially sell assets by June 2027; management provided confidence but no concrete refinancing solution.
Near term
Liquidity improved to $6.8 million at quarter-end, supplemented by $2 million of subordinated financing from an entity controlled by the Executive Chairman, but the near-term stock catalyst is likely financing progress rather than operating results.
Rhode Island direct-patient volumes, proton treatment activity, and international Gamma Knife utilization need to remain strong enough to offset the EBITDA decline and absorb ongoing debt obligations.
The $909,000 allowance against pre-May 2025 Rhode Island receivables and $285,000 of financing-related professional fees highlight continued earnings volatility.
Longer term
The direct patient services model is scaling faster than the legacy leasing business, with Rhode Island, Peru, and Mexico providing potential operating leverage if procedure volumes continue to rise.
The ESPRIT upgrade in Peru and the planned Guadalajara upgrade could improve throughput, but future Rhode Island centers and the Johnston proton project are development opportunities rather than funded earnings drivers.
The capital structure is the core long-term thesis changer: the lender agreement permits pursuit of a sale of all or part of the assets, while refinancing remains uncommitted and could dilute or impair shareholder value.
Management's claim that the platform is becoming more diversified is credible operationally, but the decline in adjusted EBITDA despite 19% revenue growth indicates that scale benefits have not yet translated into consistent profitability.
Red flags
Management did not explain the underlying cause of the $909,000 insurance-carrier receivable impairment despite direct analyst questioning, including whether the issue could recur; the response that the company was 'not proud of it' was not sufficient diligence-quality disclosure.
The third amendment and forbearance agreement requires subsidiaries to pursue a sale of some or all assets, creating material strategic and refinancing risk that management downplayed by emphasizing the 12-month maturity extension.
The $2 million insider-controlled subordinated financing improves liquidity but also underscores the company's dependence on related-party capital and does not resolve the $13.3 million projected debt balance due by June 2027.
A CFO departure and appointment of an interim CFO add execution and reporting risk while the company is negotiating financing and addressing historical receivable collection problems.
OpenFilings analyst view from primary-source filings and earnings calls — not investment advice.
Upcoming earnings
Earnings transcripts
Press & signals
- GlobeNewswire
American Shared Hospital Services Reports Second Quarter and First Half 2026 Financial Results
- Satelight
American Shared Hospital Services Reports Second Quarter and First Half
- Satelight
American Shared Hospital Services Announces Second Quarter 2026 Financial